GSK fears Synflorix may be no match for Prevnar in the US
This article was originally published in Scrip
Executive Summary
GlaxoSmithKlinehas said that it may not apply to market its new 10-valent pneumococcal vaccine Synflorix in the US because of the tough competition it would meet from Wyeth's blockbuster seven-valent vaccine Prevnar.